Dipeptidyl peptidase 4 (DPP-4) inhibitors for people with chronic kidney disease and diabetes

This is a protocol for a Cochrane Review (intervention). The objectives are as follows:

This review aims to assess the benefits and harms of DPP-4 inhibitors in people with CKD and type 2 diabetes.

This is a protocol.

Published:

29 August 2023

Authors:

Natale P, Palmer SC, Tunnicliffe DJ, Toyama T, Strippoli GFM

Was this helpful? Donate.

If you found this evidence helpful, please consider donating to Cochrane. We are a charity that produces accessible evidence to help people make health and care decisions.
Donate
Print
PDF
Citation
Natale P, Palmer SC, Tunnicliffe DJ, Toyama T, Strippoli GFM. Dipeptidyl peptidase 4 (DPP-4) inhibitors for people with chronic kidney disease and diabetes (Protocol). Cochrane Database of Systematic Reviews 2023, Issue 8. Art. No.: CD015906. DOI: 10.1002/14651858.CD015906.